Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, announced today the successful achievement of the primary endpoint ...

Compass Pathways said on Tuesday its psilocybin-based therapy eased depression symptoms in a late-stage trial, sending the ...

LONDON & NEW YORK, February 19, 2026--(BUSINESS WIRE)--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, announced ...

Compass will now seek approval for COMP360, which could become the first classic psychedelic to gain the FDA’s blessing.

Evidence of durability of psilocybin-based COMP360 is a key point for the FDA, according to Compass Pathways Chief Medical ...

Compass Pathways has reported another phase 3 win for its psilocybin therapy in treatment-resistant depression, sending the ...

Compass Pathways is rated a Hold due to high risk, funding needs, and the need for further data before reassessing the thesis ...

COMPASS Pathways CMPS shares are up during Tuesday’s premarket session following the company’s announcement of achieving the ...

In two large-scale trials, Compass Pathways' proprietary form of psilocybin improved people's depression symptoms better than controls.

Compass Pathways on Tuesday disclosed results from two Phase 3 studies that support a potential approval of its psilocybin treatment for severe depression, but more detailed data are needed to ...

Compass Pathways shares surged Tuesday after the company said its psilocybin therapy for depression met its primarily goals in recent trials. Shares traded 34% higher ahead of the morning bell at ...

Compass Pathways (CMPS) stock jumps as the company says psychedelic drug COMP360 hit late-stage trial endpoint in ...